Cargando…
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
Patients with #IPF do not mount appreciable anti-spike antibody responses to two doses of #SARSCoV2 mRNA vaccine compared to the general population. National authorities should prioritise patients with IPF for booster doses. https://bit.ly/3K2KXQ0
Autores principales: | Karampitsakos, Theodoros, Papaioannou, Ourania, Dimeas, Ilias, Tsiri, Panagiota, Sotiropoulou, Vasilina, Tomos, Ioannis, Papanikolaou, Ilias C., Katsaras, Matthaios, Kirgou, Paraskevi, Daniil, Zoe, Gourgoulianis, Konstantinos I., Sampsonas, Fotios, Manali, Effrosyni, Papiris, Spyridon, Bouros, Demosthenes, Tzouvelekis, Argyris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990384/ https://www.ncbi.nlm.nih.gov/pubmed/35509438 http://dx.doi.org/10.1183/23120541.00082-2022 |
Ejemplares similares
-
Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2021) -
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model
por: Karampitsakos, Theodoros, et al.
Publicado: (2023) -
Corrigendum: Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model
por: Karampitsakos, Theodoros, et al.
Publicado: (2023) -
Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study
por: Karampitsakos, Theodoros, et al.
Publicado: (2021) -
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)